Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 55111-596

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 55111-596). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Memantine Hydrochloride Tablets USP, 5 mg, a film-coated oral tablet. The label shows the product name, strength, and quantity of 100 tablets (10 x 10 unit-dose). It includes storage instructions and a note to dispense the patient information sheet. Manufactured by Dr. Reddy's Laboratories Limited, India. The label includes the NDC 55111-596-78 and barcode.*

FDA Label Image

Carton2 (Carton2)

Memantine Hydrochloride Tablets USP, 10 mg, film-coated oral tablets manufactured by Dr. Reddy's Laboratories Limited. The label states a package containing 100 tablets (10 x 10 unit-dose blister cards). Instructions include dispensing a patient information sheet and storage at 20°-25°C. The label displays the NDC 55111-597-78 and manufacturer details in India.*

FDA Label Image

Container1 (Container1)

Label for Memantine Hydrochloride Tablets, USP 5 mg oral film-coated tablets by Dr. Reddys Laboratories Limited. The label states the product is Rx only and contains 60 tablets. It includes storage instructions, a barcode, and a QR code linking to the patient information sheet.*

FDA Label Image

Container2 (Container2)

Memantine Hydrochloride Tablets USP 10 mg film-coated tablets, packaged in a container of 60 tablets. The label includes dosage strength, quantity, labeler Dr. Reddy's Laboratories Limited, a QR code for the patient information sheet, barcode, and storage instructions. The product is prescription only (Rx Only).*

FDA Label Image

Figure1 (Figure1)

A line graph showing mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride to placebo. The graph plots weeks of treatment on the x-axis and mean change score on the y-axis, indicating trends in clinical improvement or decline.*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage plot comparing patients taking Memantine Hydrochloride with placebo. The X-axis shows ADCS-ADL change from baseline, and the Y-axis shows the cumulative percentage of patients. Data points represent response distributions for both placebo and Memantine HCl groups.*

FDA Label Image

Figure3 (Figure3)

A line graph showing mean change from baseline in SIB scores over weeks of treatment comparing Memantine Hydrochloride and placebo. The graph illustrates clinical improvement and decline trends over a 28-week period, with error bars indicating variability.*

FDA Label Image

Figure4 (Figure4)

A cumulative percentage graph comparing patient outcomes between placebo and Memantine Hydrochloride (HCl). The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients. The graph includes two lines, with one line for placebo and another for Memantine HCl, illustrating their comparative distribution over a range of SIB changes.*

FDA Label Image

Figure5 (Figure5)

A line graph depicting mean change from baseline in ADCS-ADL score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine HCl/Donepezil groups. The x-axis represents weeks of treatment, and the y-axis shows mean change scores, illustrating clinical improvement and decline over time.*

FDA Label Image

Figure6 (Figure6)

A line graph showing the cumulative percentage of patients on the vertical axis and the ADCS-ADL change from baseline on the horizontal axis. Two treatment groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil. The graph depicts differences in patient response between these two treatments over a range of ADCS-ADL scores.*

FDA Label Image

Figure7 (Figure7)

A line graph showing the mean change from baseline in a specific score over weeks of treatment, comparing two groups labeled as Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis ranges from clinical decline to clinical improvement, and the x-axis spans 0 to 24 weeks of treatment.*

FDA Label Image

Figure8 (Figure8)

A cumulative percentage of patients graph depicting the SIB change from baseline comparing Placebo/Donepezil with Memantine HCl/Donepezil. The X-axis indicates SIB change from baseline and the Y-axis shows cumulative percentage of patients, illustrating response differences between these two treatments over a range of SIB score changes.*

FDA Label Image

Structure (Structure)

Chemical structure of Memantine Hydrochloride is shown as a bicyclic amine with two methyl groups and an attached hydrochloride (HCl). The diagram highlights the molecular framework characteristic of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.